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Abstract 
Although exposure therapy is an effective treatment for anxiety disorders, fear 
sometimes returns following successful therapy.  The Rescorla-Wagner model predicts 
that presenting two fear-provoking stimuli simultaneously (compound extinction) will 
maximize learning during exposure and reduce the likelihood of relapse.  Participants 
were either presented with single extinction trials only or single extinction trials followed 
by compound extinction trials.  Additionally, participants within each extinction group 
were randomized to caffeine or placebo ingestion prior to extinction to investigate the 
mechanism by which compound extinction may maximize learning (enhanced associative 
change or enhanced responding).  Participants presented with compound trials 
demonstrated significantly less fear responding at spontaneous recovery compared with 
participants who received single extinction trials only.  Ingestion of caffeine also 
provided some protection from spontaneous recovery (as measured by valence ratings).  
At the reinstatement test, only compound extinction trials predicted less fear responding; 
caffeine ingestion prior to extinction did not attenuate reinstatement effects.    
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Introduction 
Although the evidence for the effectiveness of exposure therapy for phobias and 
anxiety disorders is extensive (e.g., Norton & Price, 2007), fear can sometimes return 
following successful exposure therapy (e.g., Craske & Mystkowski, 2006).  Exposure 
therapy is believed to be the clinical proxy of extinction training and return of fear (ROF) 
following exposure therapy is consistent with occasions when a conditional stimulus (CS) 
re-elicits the conditional fear response (CR) following extinction: if tested in a different 
context than the extinction context (renewal; Bouton 1993), if tested after time has passed 
since extinction (spontaneous recovery; Baum, 1988), upon re-exposure to the 
unconditional stimulus (US) after extinction (reinstatement; Rescorla & Heth, 1975), or if 
the CS and US occur together again (rapid reacquisition; Kehoe & Macrae, 1997).   
These phenomena suggest that extinction is not unlearning of the previously 
learned CS-US association; instead, extinction is hypothesized to involve new inhibitory 
learning (“CS-no US”) that then competes with the CS-US memory (e.g., Bouton, 1993).  
Poor retrievability of the CS-no US memory may explain ROF following exposure 
therapy.  One method for reducing ROF is to enhance learning during extinction (i.e., 
facilitate learning of the CS-no US association) and the Rescorla-Wagner Model 
(Rescorla & Wagner, 1972) makes specific predictions for accomplishing this.  A basic 
tenet of the model is that learning (during acquisition and extinction) is determined by the 
amount of surprise, defined as the discrepancy between what is expected to occur and 
what actually occurs.  Surprise is maximized during the first few trials of acquisition or 
extinction (e.g., the US is especially surprising at the first trial of acquisition when the CS 
is neutral and expectation of an aversive event is 0).  Subsequently, learning greatly 
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diminishes because expectation becomes closer to reality, thereby minimizing surprise.  
According to the Rescorla-Wagner model, one way to maximize learning during 
extinction (and thereby potentially offset ROF) is to repeatedly elevate US-expectancy 
which provides more opportunities for discrepancy between expectation and reality.  This 
can be achieved by presenting two fear-provoking CSs simultaneously (i.e., compound 
extinction trials).   
However, extant data indicate that compound extinction blocks, rather than 
enhances, extinction learning in animals (Pineno, Zilski, & Schachtman, 2007) and 
humans (Vervliet, Vansteenwegen, Hermans, & Eelen, 2007).  These results are difficult 
to explain with elemental models of associative learning (e.g., the Rescorla-Wagner 
model) but may be explained with configural models of associative learning (e.g., Pearce, 
1987) or configural extensions of elemental models (e.g., Rescorla & Wagner, 1972).  
Elemental models of learning posit that an individual will summate the predictive values 
of each individual stimulus within a collection of stimuli whereas configural models (e.g., 
Pearce, 1987), posit than an individual will process a collection of stimuli in a 
consolidated manner.  In the case of compound trials during extinction, according to 
configural models, any new learning will be in regards to the compound stimulus rather 
than to each of the individual stimuli which comprise the compound.  Thus, it seems that 
elemental processing of the CSs is required to maximize extinction learning during 
compound trials and previous studies of compound extinction may have unintentionally 
induced configural processing of stimuli during extinction, thereby blocking extinction 
learning regarding each individual CS.  One method for facilitating elemental processing 
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of stimuli may be to present each CS on its own several times during extinction training 
prior to pairing two CSs together. 
There is evidence to support the value of this method for enhancing elemental 
processing and maximizing extinction learning: Rescorla (2006) demonstrated that, in 
pigeons and rats, using both an appetitive paradigm (CS paired with food pellet US) and 
an aversive paradigm (CS paired with foot shock US), extinction learning was optimized 
when each CS underwent separate extinction and then the two CSs were presented 
together.  Compared with animals that received single extinction trials only, animals that 
received the sequenced compound extinction trials demonstrated decreased spontaneous 
recovery and weaker reinstatement.  These results have been replicated in a recent study 
in which rats presented with sequenced compound extinction trials demonstrated 
decreased spontaneous recovery at 1-week and 4-week follow-up testing compared with 
rats that received single extinction trials only (Janak & Corbit, 2011).  Furthermore, in 
the study done by Rescorla (2006), the mechanism by which sequenced compound 
extinction trials enhances learning was also investigated: enhanced associative change (as 
predicted by the Rescorla-Wagner model) or enhanced responding (since two CSs are 
presented simultaneously, the organism is predicted to perform the conditional fear 
response at an enhanced level which can facilitate extinction learning by increasing 
adrenergic activity which has been shown to promote consolidation of emotional 
memories, Cain, Blouin, & Barad, 2004).  Results indicated that the effectiveness of the 
sequenced compound trials in enhancing extinction learning was not simply due to 
elevated responding during extinction but rather due to enhanced associative change. 
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The present study aimed to investigate whether single CS extinction trials 
followed by compound CS trials optimizes extinction learning in humans and, if so, 
whether the results are attributable to enhanced associative change or enhanced 
responding.  Following fear conditioning procedures, participants were randomly 
assigned to single extinction trials followed by compound extinction trials or single 
extinction trials only.  Participants who received compound trials were hypothesized to 
demonstrate significantly higher fear responding and elevated US-expectancy throughout 
extinction but reduced return of fear at the spontaneous recovery and reinstatement tests 
one week following extinction.  Additionally, within each extinction group, participants 
were randomly assigned to ingest caffeine or placebo prior to extinction training.  Given 
that caffeine indirectly increases adrenergic activity, ingestion of caffeine was expected 
to elevate fear responding during extinction without increasing US-expectancy.  Based on 
the findings of Rescorla (2006) and the predictions of the Rescorla-Wagner model, it was 
hypothesized that increased fear responding alone would not attenuate fear recovery at 
the spontaneous recovery and reinstatement tests.  Thus, regardless of drug ingestion, it 
was predicted that the compound extinction groups would demonstrate less fear 
responding at spontaneous recovery and reinstatement compared with single extinction 
groups. 
Method 
Design 
Participants were randomly assigned to one of four experimental groups 
according to a 2 (Extinction Group: single [S] or compound [C] stimulus trials) x 2 (Drug 
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Group: caffeine ingestion [C] or placebo ingestion [P]) design.  The distribution of 
participants across the four groups was as follows: SP = 18, CP = 18, SC = 16, CC = 18.   
Participants 
Seventy participants (49 females, 21 males), with a mean age of 19.2 (range 18 to 
23), were recruited through mass testing sessions from several Introduction to 
Psychology classes.  Participants were from a variety of ethnic backgrounds: 32.9% 
Asian, 32.9% Caucasian, 18.6% Latino, 8.5% Biracial, 4.3% Middle Eastern, 1.4% Arab, 
1.4% Indian.  Participants were recruited if they: 1) scored in the top quartile of scores on 
the Behavioral Inhibition Scale (this was done to make the results more generalizable to 
individuals with a vulnerability to developing anxiety disorders); 2) on average, ingested 
between 100mg of caffeine per week and 500mg of caffeine per day and 3) were in the 
average range (18.5-24.9) for Body Mass Index.  Exclusion criteria for study 
participation included 1) any heart, respiratory, or neurological problems, 2) current or a 
history of seizures, 3) pregnancy, and 4) current ingestion of drugs or medications which 
can interact with caffeine. 
Measures 
Self Report Questionnaires 
Two self report measures were completed at Baseline: the Behavioral Inhibition 
Scale (BIS; Carver & White, 1994) and the Beck Depression Inventory (BDI; Beck, 
Steer, & Brown 1996).  The 7-item BIS measures individual differences in the behavioral 
inhibition system, believed to regulate aversive motives in which the goal is to move 
away from something unpleasant (Carver & White, 1994).  In the current sample, α = 
0.84.  The Beck Depression Inventory is a widely used screening instrument for 
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depression with strong psychometric properties (e.g., Carmody, 2005).  In the current 
sample, α = 0.92. 
Subjective Measures 
 Across all phases of the experiment (acquisition, extinction, and test), participants 
were asked to rate their expectancy of the scream-US during CS presentations.  They 
were instructed to immediately record US-expectancy at the onset of each CS 
presentation.  This expectancy was rated on a scale between -6 = “certain no noise” to +6 
= “certain noise” with a midpoint of 0 = “uncertain.”  Participants reported valence 
ratings for each CS from -50 = “very unpleasant” to +50 = “very pleasant” with a 
midpoint of 0 = “neutral” at four time points:  immediately following acquisition, 
immediately following extinction, at spontaneous recovery, and following reinstatement.  
Physiological Measures 
 Skin conductance responses (SCRs) were measured using a Biopac MP150 unit 
running Acqknowledge 4.0 software (Biopac Systems, Inc., Goleta, CA) with a GSR 
100C amplifier set to direct current, a sensitivity of 5 μohm/V, and a 1.0-Hz low-pass 
filter.  SCRs were measured at each CS onset and provided a measure of fear arousal.  
Data were acquired at 200 samples per second.  
 To measure SCRs, two disposable 1 cm diameter AG-AgCl electrodes were 
placed on the distal phalanx of the index and middle fingers of the non-dominant hand.  
The magnitude of SCRs was calculated as the difference between the maximum skin 
conductance level (measured in microsiemens) within 1–6 seconds following CS onset 
and the mean skin conductance level within the 2-second period prior to CS onset.  
Amplitudes were range corrected using the largest response elicited by the US for each 
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individual participant.  To do this, for each participant, SCRs to each US presentation 
were calculated as the difference between the maximum skin conductance level within 1-
6 seconds following US-onset and the mean skin conductance level within the 2-second 
period prior to CS-onset (the CS which occurred immediately prior to that particular US 
presentation).  For each participant, all SCRs to CSs were divided by that person’s 
maximum SCR to the US.  These range-corrected responses were then subjected to a 
square root transformation in order to normalize the distribution prior to statistical 
analysis.  SCRs were rejected for a given CS presentation if behavioral observations 
indicated movement, including coughing and sneezing.  SCRs were scored as zero for a 
given CS presentation when there was no observable peak in skin conductance level 
within 1-6 seconds following CS onset. 
Apparatus and Stimuli 
 Three geometrical shapes (blue circle, red triangle, and green trapezoid) were 
used as the conditional stimuli (CSs).  CSA always appeared on the left side of the screen 
and CSB always appeared on the right side of the screen; both were paired with the US 
during acquisition training.  CS- always appeared in the middle of the screen and was 
never paired with the US.  Which of the three geometrical shapes served as CSA, CSB, or 
CS- was counterbalanced across participants.  The unconditional stimulus (US) was a 1-
second scream presented binaurally through headphones at 82 decibels.  Such auditory 
stimuli have successfully served as USs in previous studies (e.g., Lau et al., 2008).  In 
fact, auditory USs have been found to demonstrate equivalent or superior conditioning 
effects as shock USs without the risk of causing pain or excessive anxiety (Neumann & 
Waters, 2006).  Across different auditory US stimuli, a scream-US has been found to 
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produce more robust conditioning effects than a white noise-US (Joos, Vansteenwegen, 
& Hermans, 2012); thus a scream-US was utilized in the current study.  Stimulus delivery 
was controlled by one computer which presented participants with the CSs and US 
through E-prime software (Psychology Software Tools, Inc., Pittsburgh, PA, USA).  
Physiological data acquisition was controlled by a second computer using Acqknowledge 
software (Biopac Systems, Inc., Goleta, CA, USA). 
Procedure 
The experiment consisted of several phases that were completed over the course 
of two days.  Participants were asked to abstain from eating or drinking anything (except 
water) for 8 hours prior to the first day and were scheduled between 8am and 12pm.  A 
trained research assistant described the study procedures, obtained informed consent, and 
administered the BIS and BDI.  Electrodes for recording SCR were attached.  Next, 
psychophysiological measures was recorded for a five-minute resting period during 
which participants were instructed to “please sit quietly and remain still” and left alone 
(the researcher monitored physiological data acquisition in a room adjacent to the 
experimental room).  Next, participants were seated 3 feet in front of a 21” computer 
monitor placed at eye level which was used to display the CSs.  They were asked to put 
on headphones and told they may sometimes hear a loud noise through the headphones.  
The researcher then trained participants on the US-expectancy scale and instructed them 
to rate their expectancy of the noise as soon as soon as each shape appeared on the screen    
Experimental phases are shown in Table 1.  Across all phases, the CSs were 
presented in random order with the caveat that no more than two trials of each CS were 
presented sequentially and the inter-trial interval (ITI) varied across 20, 25, and 30 
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seconds (mean = 25 seconds).   Participants first underwent habituation: four 8-second 
presentations of each CS.  Next, participants underwent acquisition: eight 8-second 
presentations of each CS; during the last second of CSA and CSB presentation, the 
scream-US was presented through the headphones. 
-------------------------------------------------------- 
Insert Table 1 
-------------------------------------------------------- 
Following acquisition, participants removed the headphones and provided 
subjective valence ratings for each CS.  Participants were given 4 oz of grapefruit juice 
which they knew may or may not contain 600 mg of crushed caffeine pills (this dosage 
was chosen because it has been shown to safely and reliably increase physiological 
arousal; Zoellner & Craske, 1999).  The experimenter was blind to the participant’s drug 
group assignment.  Following ingestion of the juice, participants sat for 45 minutes (they 
were provided with magazines) to allow for optimal absorption of caffeine.  Then, 
another 5-minute baseline was recorded prior to commencement of extinction training.   
During the first phase of extinction, all participants received eight 8-second presentations 
of CSA, CSB, and CS- without any US presentations.  During the second phase of 
extinction, half of the participants within each drug group received eight 8-second trials 
of CSA while the other half received eight 8-second compound trials during which CSA 
and CSB appeared simultaneously next to each other on the screen.  All participants also 
received eight 8-second trials of the CS-.  Following extinction training, participants 
provided valence ratings for each CS.   
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On Day 2, participants provided valence ratings for each CS.  Electrodes were 
then attached again for SCR recording and participants put on the headphones; they were 
also re-familiarized with the US-expectancy scale.  The test phase consisted of eight 8-
second presentations of CSA and CS-, presented in random order with the caveat that no 
more than two trials of each CS were presented sequentially and with ITIs ranging across 
20, 25, and 30 seconds.  Halfway through this test phase (i.e., following four CSA and 
four CS- presentations), all participants received one scream-US presentation during an 
intertrial interval (i.e., reinstatement).  Upon completion of this phase, participants again 
provided subjective valence ratings for each CS. 
Statistical Analyses 
Baseline differences were examined using one-way ANOVAs; effect sizes 
reported for these analyses are partial eta squared.  Regression analyses and their follow-
up tests were conducted using hierarchical linear modeling (HLM; Raudenbush & Bryk, 
2002).  HLM is useful in analyzing repeated measures data (Level 1 data) nested within 
subjects (Level 2 data; Bryk, Raudenbush, & Congdon, 1996).  HLM does not require the 
assumption of independence of observations, improves the estimate of effects within 
individual units, and has lower Type I error rates (Raudenbush & Bryk, 2002).  HLM is 
essentially a program that conducts regressions and is capable of including fixed factors 
(i.e., independent variable) and multiple random factors (e.g., individuals).  It was used in 
this study to examine change across time with repeated measures for each individual.  T-
tests were used to examine whether y-intercepts of the regression lines were significantly 
different from zero and whether differences between two regression lines (e.g., regression 
line for change in SCR to CSA in compound placebo group during extinction versus 
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regression line for change in SCR to CSA in single placebo group during extinction) were 
significant.  To report effect sizes for these t-tests, Cohen’s d was calculated using the 
following formula: d = (t*2)/(sqrt(df)) where t = t-test value and df = degrees of freedom.   
Results 
Baseline 
The mean BIS score in this sample was 22.61 and the mean BDI score was 7.57.  
One-way ANOVAs revealed no significant differences among the four groups on the BIS 
(F(3,69)  = 0.25, p = 0.86, ηp
2
 = 0.01) or the BDI (F(3,69) = 0.63, p = 0.60, ηp
2
 = 0.03).  
There were also no significant differences among the groups on age (F(3,69) = 1.61, p = 
0.20, ηp
2
 = 0.07), gender (χ2(3, N = 70) = 5.22 (p = 0.16)), or ethnicity (χ2(21, N = 70)  = 
23.23 (p = 0.33)).   
Acquisition 
 Skin Conductance Response (SCR) 
 HLM analyses were conducted for SCRs to each conditional stimulus across the 
eight acquisition trials.  For CSA and CSB, the intercept was significantly different from 
zero (CSA: b = 0.28, t(61) = 4.60, p < 0.001, d = 1.18; CSB: b = 0.24, t(61) = 4.10, p < 
0.001, d = 1.05) indicating all participants demonstrated a skin conductance response 
higher than zero at the first trial of CSA and CSB.  In addition, the slope was 
significantly different from zero and positive (CSA: b = 0.03, t(439) = 3.08, p < 0.005, d 
= 0.29; CSB: b = 0.03, t(439) = 2.72, p < 0.01, d = 0.26), indicating all participants 
demonstrated a significant increase in SCRs to CSA and CSB across acquisition, 
demonstrating the effects of fear conditioning.  For CS-, the intercept was significantly 
different from zero (b = 0.36, t(61) = 4.89, p < 0.001, d = 1.25) and the slope was 
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significantly different from zero and negative (b = -0.05, t(439) = -4.26, p < 0.001, d = 
0.41) indicating all participants demonstrated a significant decline in SCRs to CS- across 
acquisition.  Thus, acquisition training was successful in that participants learned to 
demonstrate conditional fear responses to CSA and CSB and learned not to be fearful of 
the CS-. 
Expectancy Ratings 
 HLM analyses were conducted for subjective US-expectancy ratings to each 
conditional stimulus across the eight acquisition trials.  For CSA and CSB, the intercept 
was not significant indicating participants rated US-expectancy no different than zero 
(i.e., “uncertain”) at the first trial of CSA and CSB (p-values = 0.4 – 0.9).  The slope was 
significantly different from zero and positive (CSA: b= 0.49, t(355) = 3.03, p < 0.005, d = 
0.32; CSB ; b = 0.42, t(355) = 2.34, p < 0.05, d = 0.25) indicating all participants 
demonstrated a significant increase in US-expectancy ratings to CSA and CSB across 
acquisition, demonstrating the effects of fear conditioning.  For CS-, there were no 
significant effects at the intercept and participants demonstrated no change in US-
expectancy ratings across acquisition (p-values = 0.2 – 0.8).  Thus, acquisition training 
successfully taught participants to expect the US when presented with CSA or CSB. 
Pre-Acquisition Baseline to Pre-Extinction Baseline 
 A 2 (Drug Group: Placebo, Caffeine) x 2 (Time: Baseline prior to Habituation, 
Baseline prior to Extinction) ANOVA examined whether ingestion of caffeine impacted 
mean skin conductance levels during the baseline period.  Results indicated a significant 
Time x Group interaction effect (F(1,62) = 5.64, p < 0.05, ηp
2
 = 0.08).  Tests of simple 
effects indicated that participants who ingested caffeine demonstrated a significant 
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increase in mean skin conductance level from pre-acquisition baseline to pre-extinction 
baseline (F(1,62) = 9.01, p < 0.005, ηp
2
 = 0.13) whereas participants who ingested 
placebo demonstrated no change in mean skin conductance level (F(1,62) = 0.13, p = 
0.72, ηp
2
 < 0.001).  Therefore, participants who ingested caffeine demonstrated a 
significantly higher level of arousal during extinction than participants who did not. 
Extinction Phase 1 
HLM analyses were conducted for SCRs and US-expectancy ratings during each 
CS trial across Extinction Phase 1.  Participants were divided into caffeine versus placebo 
groups since drug ingestion was the only difference between participants during this 
phase. 
 Skin Conductance Response (SCR) 
For CSA, the intercept was significantly different from zero (b = 0.43, t(61) = 
7.84, p < 0.001, d = 2.01) and there was a significant difference between the caffeine 
group and the placebo group (b = -0.14, t(61) = -2.02, p < 0.05, d = 0.52) such that 
participants who ingested caffeine demonstrated significantly lower SCRs to CSA at the 
first trial of extinction compared with participants who ingested placebo.  The slope of 
SCRs to CSA was significantly different from zero (b = -0.05, t(439) = -6.30, p < 0.001, 
d = 0.60) and the group slopes were significantly different from each other (b = 0.03, 
t(439) = 3.19, p < 0.005, d = 0.30) such that participants who ingested caffeine had a 
significantly flatter slope than those who ingested placebo (i.e., participants who ingested 
caffeine did not demonstrate a decline in SCRs to CSA across Extinction Phase 1 
whereas participants who ingested placebo did demonstrate a decline in SCRs to CSA 
across this phase; see Figure 1).   
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For CSB, the intercept was significantly different from zero (b = 0.40, t(61) = 
6.09, p < 0.001, d = 1.56) but there were no group differences at the intercept (p = 0.35).  
The slope of SCRs to CSB was significantly different from zero (b = -0.04, t(439) = -
4.52, p < 0.001, d = 0.43) and the group slopes were significantly different from each 
other (b = 0.03, t(439) = 1.92, p = 0.05, d = 0.18) such that those participants who 
ingested caffeine had a significantly flatter slope than those who ingested placebo (i.e., 
participants who ingested caffeine did not demonstrate a decline in SCRs to CSB across 
Extinction Phase 1 whereas participants who ingested placebo did demonstrate a decline 
in SCRs to CSB across this phase). 
 For CS-, the intercept was significantly different from zero (b = 0.24, t(61) = 6.13, 
p < 0.001, d = 1.57) and the slope was significantly different from zero (b = -0.02, t(439) 
= -4.83, p < 0.001, d = 0.46) but there were no group differences (p-values = 0.4 – 0.9) 
indicating all participants demonstrated an SCR higher than zero to CS- at the first trial of 
Extinction Phase 1 and a significant decline in SCRs to CS- across Extinction Phase 1. 
 Expectancy Ratings 
For CSA, the only significant finding was that the slope was significantly 
different from zero (b = -0.23, t(488) = -2.25, p < 0.05, d = 0.20), indicating all 
participants demonstrated a significant decline in US-expectancy ratings to CSA across 
the first phase of extinction (non-significant p-values = 0.4 – 1.0).  For CSB, there were 
no significant findings although the slope approached significance (b = -0.20, t(488) = -
1.75, p = 0.08, d = 0.16) indicating a decline in US-expectancy ratings to CSB across 
Extinction Phase 1 (non-significant p-values = 0.3 – 0.9).  For CS-, the intercept was 
significantly different from zero (b = -2.27, t(68) = -4.16, p < 0.001, d = 1.09) and the 
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slope was also significantly different from zero (b = -0.20, t(488) = -2.56, p < 0.05, d = 
0.23) indicating all participants demonstrated a significant decline in US-expectancy 
ratings to CS- across the first phase of extinction with no group differences at the 
intercept or in the slopes (p-values = 0.3 – 0.7). 
Change from Extinction Phase 1 to Extinction Phase 2 
 Skin Conductance Response (SCR) 
 For CSA, a 4 (Group: SP, CP, SC, CC) x 2 (Time: Extinction Phase 1 Trial 8, 
Extinction Phase 2 Trial 1) repeated measures ANOVA revealed a significant effect of 
Time (F(1,59) = 33.95, p < 0.001, ηp
2
 = 0.37), Group (F(3,59) = 7.78, p < 0.001, ηp
2
 = 
0.28), and Time x Group interaction (F(3,59) = 9.00, p < 0.001, ηp
2
 = 0.31).  CP and CC 
group participants demonstrated a significant increase in SCR from the last trial of 
Extinction Phase 1 to the first trial of Extinction Phase 2 (CP: F(1,59) = 24.58, p < 0.001, 
ηp
2
 = 0.29; CC: F(1,59) = 34.96, p < 0.001, ηp
2
 = 0.37) whereas SP and SC group 
participants did not (SP: F(1,59) = 0.62, p = 0.43, ηp
2
 = 0.01; SC: F(1,59) = 0.01, p = 
0.94, ηp
2
 < 0.001).  Thus, participants in the two compound extinction groups (CP and 
CC) demonstrated a significant increase in physiological fear response when first 
presented with the compound stimulus; see Figure 1.   
Expectancy Ratings 
For CSA, there was a significant effect of Time (F(1,66) = 9.73, p < 0.005, ηp
2
 = 
0.13) and Time x Group interaction (F(3,66) = 5.68, p < 0.005, ηp
2
 = 0.21).  CP and CC 
group participants demonstrated a significant increase in US-expectancy ratings from the 
last trial of Extinction Phase 1 to the first trial of Extinction Phase 2 (CP: F(1,66) = 
20.50, p < 0.001, ηp
2
 = 0.24; CC: F(1,66) = 6.46, p < 0.05, ηp
2
 = 0.10) whereas SP and SC 
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group participants did not (SP: F(1,59) = 0.03, p = 0.87, ηp
2
 < 0.001; SC: F(1,59) = 0.71, 
p = 0.40, ηp
2
 = 0.01).  Thus, participants in the two compound extinction groups (CP and 
CC) demonstrated a significant increase in US-expectancy rating when first presented 
with the compound stimulus. 
-------------------------------------------------------- 
Insert Figure 1 
-------------------------------------------------------- 
Extinction Phase 2 
HLM analyses were conducted for SCRs and US-expectancy ratings during each 
CS trial across Extinction Phase 2.   
 Skin Conductance Response (SCR): CSA 
For CSA, the intercept was significantly different from zero (b = 0.18, t(61) = 
2.54, p = 0.01, d = 0.65) and there were significant group differences at this intercept (b = 
0.14, t(61) = 3.27, p < 0.005, d = 0.84).  There was no significant slope effect (p = 0.34) 
but there were significant group slope differences (b = -0.01, t(439) = -2.60, p = 0.01, d = 
0.25).  To more closely examine these group differences, pairwise HLM analyses were 
conducted.   
SP versus CP: What is the impact of compound trials on extinction? 
The intercept was not significantly different from zero (p = 0.17) but there were 
significant group differences at the intercept (b = 0.64, t(29) = 5.14, p < 0.001, d = 1.91) 
indicating CP group participants demonstrated a significantly higher SCR at the first trial 
of the second phase of extinction than SP group participants.  There was no significant 
slope effect (p = 0.14) but there were significant group slope difference (b = -0.05, t(215) 
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= -2.69, p< 0.01, d = 0.37) indicating CP had a significantly steeper negative slope than 
SP.  Thus, participants in the Compound Placebo group demonstrated significantly higher 
physiological fear responses to CSAB at the start of Extinction Phase 2 than Single 
Placebo group participants did to CSA and CP group participants demonstrated a steeper 
decline in SCRs to CSAB across this phase than did SP group participants to CSA.   
SP versus SC: What is the impact of caffeine on extinction? 
The intercept was not significantly different from zero (p = 0.17) but there were 
significant group difference at the intercept (b = 0.07, t(30) = 2.01, p = 0.05, d = 0.73) 
indicating SC group participants demonstrated a significantly higher SCR at the first trial 
of the second phase of extinction than SP group participants.  Therefore, participants in 
the Single Caffeine group demonstrated significantly higher physiological fear responses 
to CSA at the start of Extinction Phase 2 than did Single Placebo group participants.  
There was no significant slope effect (p = 0.14) and no significant group slope 
differences (p = 0.79). 
SC versus CC: What is the impact of caffeine on the difference between single and 
compound trials during extinction? 
The intercept was significantly different from zero (b = -0.78, t(30) = -2.57, p < 
0.05, d = 0.94) and there was a significant difference between the groups (b = 0.48, t(30) 
= 3.58, p = 0.001, d = 1.31) indicating CC group participants demonstrated a significantly 
higher SCR at the first trial of the second phase of extinction than SC group participants.  
Similarly, the slope was significantly different from zero (b = 0.14, t(222) = 3.43, p < 
0.001, d = 0.46) and there was a significant difference between the groups (b = -0.07, 
t(222) = -3.75, p< 0.001, d = 0.50) indicating CC had a significantly steeper negative 
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slope than SC.  Similar to the differences between groups CP and SP, Compound 
Caffeine group participants demonstrated significantly elevated physiological fear 
responses to CSAB at the start of Extinction Phase 2 than Single Caffeine group 
participants did to CSA and CC group participants demonstrated a steeper decline in 
SCRs to CSAB across this phase than did SC group participants to CSA.   
 Skin Conductance Response (SCR): CS- 
For CS-, the intercept was significantly different from zero (b = 0.12, t(61) = 2.66, 
p = 0.01, d = 0.68) and there were significant group differences at this intercept (b = 0.06, 
t(61) = 2.52, p < 0.05, d = 0.65).  There was no significant slope effect (p = 0.72) and no 
significant group slope differences (p = 0.23).  To more closely examine the group 
differences at the intercept, pairwise HLM analyses were conducted.  
SP versus CP: What is the impact of compound trials? 
There were no significant findings for the intercept, group differences at the 
intercept, slope effect, or group slope differences (p-values = 0.1 – 0.7).  Thus, there were 
no differences between Single Placebo and Compound Placebo group participants in 
physiological fear responding to CS- during Extinction Phase 2. 
SP versus SC: What is the impact of caffeine? 
The only significant finding was group difference at the intercept (b = 0.16, t(30) 
= 3.27, p < 0.005, d = 1.19) indicating SC group participants demonstrated a significantly 
higher SCR to CS- at the first trial of the second phase of extinction than SP group 
participants.  Thus, Single Caffeine group participants demonstrated significantly higher 
physiological fear responses to CS- at the start of Extinction Phase 2 compared to Single 
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Placebo group participants.   There were no significant effects for the intercept, slope, or 
group slope differences (p-values = 0.1 – 0.4). 
SC versus CC: What is the impact of caffeine on the difference between single and 
compound trials? 
The intercept was significantly different from zero (b = 0.70, t(30) = 2.37, p < 
0.05, d = 0.87) but there were no significant group differences at the intercept (p = 0.14), 
indicating participants in both groups demonstrated SCRs higher than zero to CS- at the 
first trial of Extinction Phase 2.  There was no significant slope effect (p = 0.21)and no 
significant group slope differences (p = 0.41).  Thus, there were no differences between 
Single Caffeine and Compound Caffeine group participants in physiological fear 
responding to CS- during Extinction Phase 2. 
 Expectancy Ratings: CSA 
For CSA, the intercept (i.e., the US-expectancy rating at the first trial of the 
second phase of extinction training) was significantly different from zero (b = 1.41, t(68) 
= -2.18, p < 0.05, d = 0.53) but there were no significant group differences (p = 0.30).  
The slope was significantly different from zero (b = -0.27, t(488) = -2.84, p = 0.005, d = 
0.26) but there were no group slope differences (p = 0.53).  Although this analysis did not 
reveal a significant group difference at the intercept, given the a priori hypothesis that 
compound versus single trials would have an impact on expectancy ratings, pairwise 
HLM analyses were conducted. 
SP versus CP: What is the impact of compound trials on extinction? 
Analyses revealed no significant intercept effect, group differences at the 
intercept, or slope effect (p-values = 0.1 – 0.2). However, there was a significant group 
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slope difference (b = 0.52, t(250) = -3.59, p < 0.001, d = 0.45) indicating that CP group 
participants had a significantly steeper negative slope than SP group participants.  So, 
participants in the Compound Placebo group demonstrated a significantly greater decline 
in US-expectancy ratings (to CSAB) across Extinction Phase 2 than did Single Placebo 
group participants (to CSA). 
SP versus SC: What is the impact of caffeine? 
Analyses revealed no significant findings indicating no group differences between 
groups Single Placebo and Single Caffeine in US-expectancy ratings to CSA across 
Extinction Phase 2 (p-values = 0.1 – 1.0). 
SC versus CC: What is the impact of caffeine on the difference between single and 
compound trials? 
Analyses revealed that the intercept was significantly different from zero (b = -
9.13, t(32) = -2.54, p < 0.05, d = 0.90) and there was a significant difference between the 
groups (b = 3.28, t(32) = 2.35, p < 0.05, d = 0.83), indicating that the mean expectancy 
ratings reported by CC group participants was significantly higher than reported by SC 
group participants.  Thus, participants in the Compound Caffeine group reported 
significantly higher US-expectancy ratings to CSAB at the start of Extinction Phase 2 
than did Single Caffeine group participants to CSA.  There was no significant slope effect 
and no significant group slope differences (p-values = 0.1 – 0.3). 
 Expectancy Ratings: CS- 
For CS-, the intercept was significantly different from zero in the negative 
direction (b = -3.56, t(68) = -5.63, p < 0.001, d = 1.36).  There were no significant 
findings for group differences at the intercept, slope, or group slope differences (p-values 
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= 0.3 – 0.4).  Pairwise HLM analyses also indicated the intercept was significantly 
different from zero in the negative direction (SP versus CP: b = -3.30, t(34) = -4.26, p < 
0.001, d = 1.46; SP versus SC: b = -3.30, t(32) = -4.26, p < 0.001, d = 1.51; SC versus 
CC: b = 0.70, t(30) = 2.37, p < 0.05, d = 0.87).  There were no group differences at the 
intercept, no significant slope effect, and no group slope differences (p-values = 0.2 – 
0.7).   Therefore, all participants provided US-expectancy ratings significantly negative 
from zero to CS- during Extinction Phase 2, indicating they did not expect to experience 
the US when presented with CS-. 
Change from Endpoint of Extinction to Spontaneous Recovery Test 
 Skin Conductance Response (SCR) 
  For CSA, a 4 (Group: SP, CP, SC, CC) x 2 (Time: End of Extinction, 
Spontaneous Recovery Test) repeated measures ANOVA revealed a significant effect of 
Time (F(1,59) = 13.64, p < 0.001, ηp
2
 = 0.19), Group (F(3,59) = 3.31, p < 0.05, ηp
2
 = 
0.14), and their interaction (F(3,59) = 6.01, p = 0.001, ηp
2
 = 0.23).  SP group participants 
demonstrated a significant increase in SCR from End of Extinction to Spontaneous 
Recovery (F(1,59) = 27.94, p < 0.001, ηp
2
 = 0.32) whereas CP, SC, and CC group 
participants did not (CP: F(1,59) = 0.29, p = 0.59, ηp
2
 = 0.01; SC: F(1,59) = 3.12, p = 
0.08, ηp
2
 = 0.05; CC: F(1,59) = 0.91, p = 0.34, ηp
2
 = 0.02).  So, participants in the Single 
Placebo group demonstrated significant spontaneous recovery of a previously 
extinguished physiological fear response while participants in the remaining three groups 
did not. 
 Expectancy Ratings 
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For CSA, Time was significant (F(1,66) = 24.68, p < 0.001, ηp
2
 = 0.27) indicating 
all participants demonstrated a significant increase in US-expectancy ratings from End of 
Extinction to Spontaneous Recovery (Group: F(3,66) = 2.06, p = 0.11, ηp
2
 = 0.09; Time x 
Group: F(3,66) = 0.98, p = 0.41, ηp
2
 = 0.04).  Thus, all participants demonstrated 
significant spontaneous recovery of a previously extinguished subjective fear response as 
measured by US-expectancy ratings. 
Spontaneous Recovery Test 
 Skin Conductance Response (SCR) 
 A one-way ANOVA revealed a significant effect of Group at the first trial of CSA 
at one-week follow-up (F(3,61) = 6.21, p = 0.001, ηp
2
 = 0.19; Figure 2).  A series of 
independent-samples t-tests revealed that SCR was significantly higher in SP than CP 
(t(30) = 4.67, p < 0.001, r = 0.65) and in SP than CC (t(30) = 2.78, p < 0.01, r = 0.45).  
SP versus SC and SC versus CC revealed no significant differences (p-values = 0.1 – 
0.3). 
 A one-way ANOVA revealed a significant effect of Group at the first trial of CS- 
at one-week follow-up (F(3,63) = 2.68, p = 0.05, ηp
2
 = 0.18).  A series of independent-
samples t-tests revealed that SCR was significantly higher in SP than CP (t(29) = 2.80, p 
< 0.01, r = 0.46) and in SP than CC (t(30) = 2.09, p < 0.05, r = 0.36).  SP versus SC and 
SC versus CC revealed no significant differences (p-values = 0.3 – 0.4). 
-------------------------------------------------------- 
Insert Figure 2 
-------------------------------------------------------- 
 Expectancy Ratings 
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One-way ANOVAs revealed no significant Group effect at the first trial of CSA 
(Figure 3) or at the first trial of CS- at one-week follow-up (p-values = 0.4 – 0.8).  
 Valence Ratings 
A one-way ANOVA revealed a significant effect of Group at one-week follow-up 
(F(3,65) = 3.32, p < 0.05, ηp
2
 = 0.13).  CSA was rated significantly more unpleasant in SP 
than CP (t(34) = -2.69, p = 0.01, d = 0.92) and in SP than SC (t(31) = -2.79, p < 0.01, d = 
1.00).  There was a trend for CSA to be rated more unpleasant in SP than CC (t(34) = -
1.93, p = 0.06, d = 0.66).  SC versus CC revealed no significant differences (p = 0.25).  
For CSB and CS-, there were no significant findings (p-values = 0.4 – 0.5). 
-------------------------------------------------------- 
Insert Figure 3 
-------------------------------------------------------- 
Reinstatement Test 
 Skin Conductance Response (SCR) 
 For CSA, a one-way ANOVA revealed a significant effect of Group at the first 
trial following reinstatement (F(3,65) = 3.42, p < 0.05, ηp
2
 = 0.18; Figure 2).  A series of 
independent-samples t-tests revealed that SCR was higher in SP than CP (t(30) = 3.13, p 
< 0.005, d = 1.14).  For CS-, a one-way ANOVA revealed a nonsignificant trend towards 
a Group effect at the first trial following reinstatement (F(3,63) = 2.40, p = 0.08, ηp
2
 = 
0.11).   
  Expectancy Ratings 
For CSA, there was a significant effect of Group at the first trial following 
reinstatement (F(3,69) = 3.51, p < 0.05, ηp
2
 = 0.14; Figure 3).  Independent samples t-test 
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revealed that expectancy ratings were significantly higher in SP than CP (t(34) = 2.87, p 
< 0.01, d = 0.98) and in CP than CC (t(34) = -2.89, p < 0.01, d = 0.99).  SP versus SC and 
SC versus CC revealed no differences (p-values = 0.2 – 0.3).  For CS-, there were no 
group differences (F(3,69) = 1.70, p = 0.18, ηp
2
 = 0.07). 
Discussion 
This study tested the hypothesis that compound stimulus presentations during 
extinction would enhance extinction learning and lead to less recovery of conditional fear 
responding at spontaneous recovery and reinstatement tests.  The mechanism was 
hypothesized to be enhanced discrepancy between expectation and reality (i.e., enhanced 
associative change) rather than enhanced conditional responding during extinction.  As 
such, ingestion of caffeine was hypothesized to have no impact on recovery of fear.  
These results largely supported the study hypotheses. 
Spontaneous Recovery 
The impact of compound extinction trials 
At spontaneous recovery, the Compound Placebo group demonstrated 
significantly lower fear arousal (i.e., SCRs) to CSA than Single Placebo, even though 
fear responding remained more elevated in the Compound Placebo group during 
extinction.  This was also demonstrated in the difference from the end of extinction to 
spontaneous recovery: Single Placebo group participants demonstrated significant 
recovery of physiological fear responding whereas Compound Placebo group participants 
did not.  Furthermore, Compound Caffeine demonstrated significantly less fear arousal 
(i.e., SCRs) to CSA at spontaneous recovery than did Single Placebo.  Thus, regardless of 
drug group assignment, participants presented with compound trials during extinction 
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demonstrated significantly less physiological conditional fear responding to CSA than 
participants in the Single Placebo group at the one-week spontaneous recovery test. 
 Subjective valence ratings provided further evidence for the effectiveness of 
compound extinction trials in attenuating fear recovery.  Compound Placebo group 
participants rated CSA as significantly less aversive at spontaneous recovery than did 
Single Placebo group participants.  Compound Caffeine group participants also rated 
CSA as less aversive than Single Placebo participants although this trend did not quite 
reach significance.   
US-expectancy data, however, did not converge with skin conductance and 
valence rating results.  There is a body of literature indicating that subjective expectancy 
ratings sometimes do not converge with physiological indices of fear responding 
(McAndrew, Jones, McLaren, & McLaren, 2012).  Most likely, this is due to expectancy 
ratings being influenced by a myriad of cognitive factors (e.g., Tune, 1964) whereas 
physiological indices are not.  For example, participants may have based US-expectancy 
ratings at spontaneous recovery on a belief such as “I know this shape was paired with 
the sound last time; so, this time, maybe the other shape will be paired with the sound.”   
In summary, both skin conductance responses and subjective valence ratings 
indicated compound extinction trials provided protection from spontaneous recovery 
effects one week following extinction training.  This is consistent with findings reported 
by Rescorla (2006) and extends those findings to humans. 
The impact of caffeine 
Interestingly, valence ratings indicated some benefit to ingesting caffeine prior to 
extinction training: Single Caffeine group participants rated CSA as significantly less 
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aversive than Single Placebo group participants at spontaneous recovery.  Caffeine 
ingestion led to enhanced conditional fear arousal during extinction; therefore, as 
predicted by the findings of Cain and colleagues (2004), enhanced fear responding (i.e., 
increased adrenergic activity) alone during extinction may enhance consolidation of 
extinction memories and thereby provide some protection against spontaneous recovery 
effects.  However, there were no effects of SCR or US expectancy ratings.   
Reinstatement 
 At the reinstatement test, among those who did not ingest caffeine, participants 
presented with compound extinction trials demonstrated significantly less conditional 
fear responding to CSA (as measured by skin conductance responses and US-expectancy 
ratings) than participants presented with single extinction trials only.  Among those who 
ingested caffeine, there were no differences between compound and single extinction 
groups.  Interestingly, Compound Placebo group participants demonstrated significantly 
lower US-expectancy ratings at reinstatement than Compound Caffeine participants.  
Taken together, these findings indicate that compound trials during extinction protected 
against reinstatement effects whereas ingestion of caffeine provided no protection against 
reinstatement.     
Fear Responding to CS- 
 Group differences in fear responding to CS- at spontaneous recovery and 
reinstatement were unexpected and interesting.  At spontaneous recovery, SCRs to CS- 
were significantly lower in both compound extinction groups than in the Single Placebo 
group.  At reinstatement, SCRs to CS- were significantly lower in the Compound Placebo 
group than in both of the single extinction groups; furthermore, Compound Placebo 
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group participants demonstrated significantly lower US-expectancy to CS- than Single 
Placebo participants.  Taken together, these findings indicate that compound extinction 
trials predicted lower fear responding to safety signals at one-week follow-up testing.  A 
possible explanation for this derives from predictions of the Rescorla-Wagner model that 
each CS is comprised of several elements and there are shared common elements 
between stimuli.  Thus, when two shape-CSs (CSA and CSB) were paired with the US, 
common elements shared between CSA, CSB, and CS- also became associated with the 
US eliciting some fear responding to the CS-.  Participants in this study did indeed 
demonstrate some fear responding to CS- (although much greater responding to CSA and 
CSB).  During extinction, it was logistically impossible to equate number of extinction 
trials, spacing of extinction trials, and stimuli presented between the compound and 
single groups; thus, participants in the compound extinction groups received twice as 
many CSB presentations during extinction.  Therefore, any shared elements between 
CSB and CS- underwent twice as many extinction trials in the compound groups than in 
the single extinction groups which may explain the differences in fear responding to CS- 
at test. 
Conclusion 
 Overall, these findings suggest that compound stimulus presentations during 
extinction enhance learning and provide protection from spontaneous recovery and 
reinstatement effects.  In addition, enhanced associative change appears to largely explain 
the findings rather than enhanced fear responding alone since caffeine ingestion prior to 
extinction training provided limited protection against spontaneous recovery (only as 
measured by subjective valence ratings) and no protection against reinstatement.  Thus, 
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compound extinction trials appear to enhance extinction learning by increasing 
expectancy of an aversive outcome which maximizes the discrepancy between 
expectation and reality, thereby driving learning as predicted by the Rescorla-Wagner 
model.   
The current study yielded different results from a previous study of compound 
extinction in humans in which extinction learning was blocked when participants were 
presented with compound trials (Vervliet et al., 2007).  Participants in that study may 
have processed the compound extinction trials as a new stimulus as predicted by 
configural models of learning (Pearce, 1987).  In contrast, participants in the current 
study were first presented with single extinction trials of each CS+ shape before the two 
shapes were paired together for compound trials in an effort to activate elemental 
processing of the stimuli.  At the conclusion of the study, participants in the compound 
extinction groups all stated they experienced the compound trials as two of the old shapes 
appearing together (i.e., they processed the compound trials elementally).  Therefore, 
presenting fearful stimuli individually first prior to pairing them together seems 
imperative.  These results are also in line with a body of literature demonstrating that 
additional extinction of a CS exhibiting any type of fear restoration deepens extinction 
learning (e.g., Hendry, 1982; Rescorla, 2006; Leung & Westbrook, 2012).  It seems that 
any method for increasing expectancy of an aversive outcome during extinction provides 
opportunity for further learning regarding the CS-no US relationship and compound 
extinction trials are one technique for doing so. 
Limitations 
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 One potential limitation is that BIS scores were not as elevated as in individuals 
with anxiety disorders, perhaps making the results less generalizable to those with a 
vulnerability to develop anxiety disorders.  However, BIS scores were still elevated 
above the mean reported in nonanxious samples and participants in this sample 
demonstrated significant fear conditioning indicating the results of extinction training 
should be relevant in enhancing the effectiveness of exposure therapy.  A second possible 
limitation is that the US may not be as aversive as are the unconditional stimuli in the 
context of anxiety disorders.  However, participants demonstrated significant 
physiological fear responding to the US indicating it was sufficiently aversive.   
Clinical Implications 
 These results suggest the effects of exposure treatments for anxiety disorders may 
be enhanced if individuals are first exposed to one fear-provoking stimulus at a time and 
then exposed to two fear-provoking stimuli in compound.  For example, in the treatment 
of panic disorder, individuals often conduct exposures to internal cues of panic attacks, 
then external cues of panic attacks, and then both simultaneously (e.g., Craske & Barlow, 
2007).  The current investigation provides a rationale for the effectiveness of such a 
paradigm.  This can be done in the treatment of other anxiety disorders as well.  For 
example, in exposure treatment for post-traumatic stress disorder, treatment effects 
should be enhanced by completing exposure to the trauma memory, exposure to 
situational reminders of the trauma, and then the combination of exposure to the trauma 
memory in the presence of situational reminders to the trauma.  It will be important for 
future studies to replicate the findings reported here and to investigate whether compound 
stimulus presentations during exposure enhances treatment effectiveness in clinical 
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samples.  More generally, these results indicate that exposure therapy may benefit from 
any method which restores fear responding to the anxiety-provoking stimuli and then 
subjects this restored fear to additional exposure therapy.  This will be an important line 
of future research, especially given that it is quite different from how exposure therapy is 
traditionally conducted. 
 Future Directions 
 The most important future studies following from the results presented here 
would be to investigate whether sequenced compound stimulus presentations enhance the 
effectiveness of exposure therapy for anxiety disorders.  This could easily be investigated 
in a sample of patients with Social Anxiety Disorder, Posttraumatic Stress Disorder, 
Panic Disorder, or Obsessive-Compulsive Disorder (OCD).  For example, in a sample of 
patients with Panic Disorder, one group could be randomly assigned to complete 
exposures to interoceptive cues of panic attacks and separate exposures to external cues 
of panic attacks but never complete exposures to these cues in compound.  The second 
group of patients would be randomly assigned to complete separate exposures to 
interoceptive cues, external cues, and then the two in compound.  Comparing these 
groups on measures of Panic Disorder symptoms at post-treatment as well as follow-up 
assessments (ideally 3-month intervals for up to 18 months post-treatment) would 
indicate whether sequenced compound exposures truly predict better treatment outcomes.  
Additionally, patients could be assigned to ingest caffeine or placebo prior to exposures 
in order to assess the mechanism by which compound exposures enhance treatment 
effects, if they do.   
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 Another line of important research would be to investigate the effectiveness of 
sequenced compound exposure when the two stimuli presented in compound do not 
predict the same aversive outcome.  For example, a patient with OCD may have 
contamination-related feared stimuli such as doorknobs (i.e., the CSs) in which the feared 
aversive outcome (i.e., the US) is contracting an illness and accident-related feared 
stimuli such as checking the stove multiple times prior to leaving their home in which the 
feared aversive outcome is accidentally causing a fire.  In this case, the USs are different: 
contracting an illness and causing a fire.  It would be important to investigate whether 
sequenced compound exposures optimize treatment effects here.  In the current 
investigation as well as all other investigations of compound extinction, the USs have 
been identical.  According to the Rescorla-Wagner model, compound exposure is 
effective because presenting the fear-provoking stimuli in compound enhances 
expectation of the US which enhances discrepancy between expectation and reality 
thereby driving learning.  It is not clear what happens when the USs are different.  
Presumably, compound exposure may still enhance treatment effects because expectation 
of an aversive event (regardless of what that event is) is enhanced when multiple fear-
provoking stimuli are present simultaneously; however, it would be important for future 
studies to investigate this. 
 In sum, the most important future studies based on these results would investigate 
whether or not sequenced compound exposures can increase response rates and decrease 
relapse rates in the treatment of anxiety disorders.  Such studies would provide vitally 
important information to clinicians regarding the ideal method for designing exposure 
exercises for their patients. 
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Table/Figure Captions 
 
Table 1: Experimental phases completed during Day 1 and Day 2. 
 
Figure 1: Slopes of skin conductance responses to CSA or CSAB across extinction.  
During Extinction Phase 1, participants were divided into Caffeine versus Placebo groups 
since drug ingestion is the only difference between participants during this phase.   
 
Figure 2: Skin conductance responses to CSA at the spontaneous recovery and 
reinstatement tests.   
 
Figure 3: Expectancy Ratings to CSA at the spontaneous recovery and reinstatement 
tests. 
